• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

RenovoRx raises $7m for drug-device pancreatic cancer therapy

May 23, 2018 By Sarah Faulkner

RenovoRx wins label expansion for RenovoCath deviceRenovoRx said today that it closed a $7 million tranche in a $10 million round to fund the development of its drug-device combination product designed to deliver chemotherapy directly to tumors in patients with locally advanced pancreatic cancer.

The company’s round was led by Boston Scientific (NYSE:BSX) and joined by btov Partners, Astia Angels, Golden Seeds and others.

The RenovoCath system is a dual-balloon infusion catheter that can deliver chemotherapy to a tumor inside the pancreas, according to RenovoRx, without the need to identify blood vessels near the treatment site.

The company touted results from a feasibility study showing that its approach yields an improved survival benefit for people with advanced pancreatic cancer compared to historical controls.

“There are significant challenges in treating pancreatic cancer and our aim is to overcome these barriers by using a catheter-based, targeted approach to delivering chemotherapy. This funding, along with our FDA orphan drug designation and approval of our IND are three important milestones in bringing this new therapy option to patients,” CEO Shaun Bagai said in prepared remarks.

The FDA has cleared the company to launch a pivotal Phase III trial of its technology and enrollment has already begun, RenovoRx reported. The 300-patient trial is slated to compare intra-arterial chemotherapy via RenovoCath to systemic chemotherapy. The primary endpoint is overall survival.

The RenovoCath device is already approved for the delivery of therapeutic agents to segments of the peripheral vasculature system. In March, RenovoRx won 510(k) clearance from the FDA to expand the product’s indication to include the delivery of chemotherapeutics.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Oncology, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Boston Scientific, RenovoRx

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS